Close Menu

NEW YORK (GenomeWeb) – Vela Diagnostics today announced a collaboration with France's Gustave Roussy Institute of Oncology on next-generation based cancer testing.

The collaboration will focus on both solid and liquid tumor diagnostics using Vela's Sentosa NGS platform. Gustave Roussy, located just outside Paris, recently implemented the Sentosa platform to diagnose melanoma, colorectal cancer, and non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.